



ALNYLAM PHARMACEUTICALS UK 2019 PATIENT ORGANIZATION SUPPORT

Alnylam Pharmaceuticals UK has voluntarily agreed to abide by the PMCPA Code of Practice and supports the efforts of the ABPI to increase transparency in the pharmaceutical industry.

In accordance with Clause 27 of the PMCPA Code of Practice for the Pharmaceutical Industry, this document lists UK patient organizations to which Alnylam provided support to in 2019.

For financial support, the date of payment has been used to determine the year in which support will be declared (e.g., if an agreement was signed in December 2019 but the payment for this agreement was made in January 2020, the support will be declared as having taken place in 2020 in the disclosure that will be made in 2021).

UK ATTR Amyloidosis Patients Association (UKATPA)

- The UKATPA applied to Alnylam for an educational grant and was awarded a grant of £6,800 to support its educational activities
- Alnylam was a sponsor of the UK ATTR Patient and Family Info Day. This sponsorship took the form of Alnylam paying for production services for the day to be filmed. The cost of these production services was £5,930
- Alnylam funded one member of the UKATPA committee to attend an Alnylam organized summit meeting in Amsterdam. The cost of this funding (including economy class flights, transfers, hotel accommodation etc.) was \$1,488.23 in total
- Alnylam contracted with a member of the UKATPA committee to provide training to internal Alnylam teams about amyloidosis from a patient's viewpoint, attend 2 advisory boards and to take part in photography for a disease awareness campaign. The total cost of these activities (including fees and all expenses) was £1662.26. The patient was representing their own views (and not the views of UKATPA) and was not a committee member of UKATPA when some of these activities took place but this is being disclosed here for transparency

Cardiomyopathy UK

- Alnylam provided sponsorship of £3,500 to Cardiomyopathy UK to support an educational meeting that aimed to educate clinicians on cardiomyopathy

British Porphyria Association (BPA)

- The BPA applied to Alnylam for an educational grant and was awarded a grant of £30,000 to support their educational projects and activities
- The BPA also applied to Alnylam for a travel grant and was awarded a grant of \$2,100
- Alnylam funded two members of the BPA committee to attend an Alnylam organized summit meeting in Amsterdam. The cost of this funding (including economy class flights, transfers, hotel accommodation etc.) was \$1,718.03 and \$1,515.77 in total
- Alnylam contracted with a member of the BPA committee to provide training to internal Alnylam teams about porphyria from a patient's viewpoint and to take part in photography for a disease awareness campaign. This committee member was paid a total of £910. The patient was representing their own views (and not the views of the BPA) but this is being disclosed here for transparency

UK Certificate

Document Number: MED-UK-General-2000005

Document Name: General_EXT_Alnylam UK 2019 PAG Support

Product: General

Planned Date of First Use: 15 Jun 2020

Allowed Audience: HCP, Non-HCP

Distributed: true

Job Category:

Document Type: Patient Advocacy

Originator:

Certification Statement

Promotional material: I have examined the final form of the material and in my belief it is in accordance with the requirements of the relevant advertising regulations and the PMCPA Code and is not inconsistent with the Marketing Authorisation and the summary of product characteristics and is a fair and truthful presentation of the facts about the medicine

Educational material for patients and the public/ patient group agreements/ services to medicine: I have examined the final form of the material and in my belief it complies with the PMCPA Code

International travel: I have examined all the proposed arrangements for the meeting and in my belief the arrangements are in accordance with the relevant advertising regulations and the PMCPA Code

Printed Final Form (if Applicable)

The following signature is for final item check purposes, and I certify that the physical version has been seen and is approved in its final form.

Role		Signature
UK Certification I have examined the final form of the material and in my belief it complies with the PMCPA Code		Stephen Lombardelli slombardelli@alnylam.com Certifier 12-Jun-2020 16:48:42 GMT+0000

--	--	--